MeSH tree: E05.478.550.520
Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. But in some patients, ...
13 hours ago
0
2
In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, ...
Jul 22, 2026
0
7
A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal. The clinical ...
Jul 14, 2026
0
5
Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival ...
Jul 7, 2026
0
6
Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized. By combining genetic and proteomic analyses, the scientists ...
Jul 3, 2026
0
6
Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells. The ...
Jun 26, 2026
0
6
Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers scientists' expertise to find viable target antigens for CAR T cell therapy. The work was led by ...
Jun 25, 2026
0
10
Researchers at the Icahn School of Medicine at Mount Sinai have found that wearable devices may help clinicians detect cytokine release syndrome (CRS)—a common and potentially serious side effect of CAR-T cell therapy—hours ...
Jun 22, 2026
0
5
Early results from a UCL- and UCLH-led clinical trial suggest that a type of CAR T-cell therapy—developed by Autolus Therapeutics, a UCL spinout—could offer a new treatment approach for people with severe, treatment-resistant ...
Jun 15, 2026
0
11
Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response to CAR T-cell therapy, a treatment for patients with recurrent or difficult-to-treat blood cancers.
Jun 15, 2026
0
4
